In the Journals

Reverse switch from biosimilar to Remicade produces similar IBD outcomes

January 14, 2019
Patients with inflammatory bowel disease who switched from biosimilar infliximab to Remicade experienced similar results regarding remission, trough…

Price hikes on older, brand-name drugs share blame for surging drug costs

January 11, 2019
The pharmaceutical industry, in recent years, has been marked by a cycle of outrage from patient groups, insurers and politicians each time a…
In the Journals

Opioid use doubled in patients with RA from 2002 to 2015

December 19, 2018
Persistent opioid use among patients with rheumatoid arthritis doubled from 2002 to 2015, with pain and antidepressant treatment being the strongest…
FDA News

Gottlieb decries 'anti-competitive practices' delaying biosimilar testing

December 11, 2018
FDA Commissioner Scott Gottlieb, MD, on Tuesday announced a series of guidance documents aimed at expanding the availability of biosimilar drugs…
In the Journals

Infliximab biosimilar safe, effective for Crohn’s disease

December 10, 2018
The biosimilar of infliximab, CT-P13, demonstrated equivalency in safety and efficacy for the treatment of Crohn’s disease, according to data…
In the JournalsPerspective

Outcomes after switching to Enbrel biosimilar influenced by patient-related factors

December 4, 2018
Adjusted treatment retention rates after 1 year were lower among patients who switched from etanercept to a biosimilar compared with the historic…
FDA News

FDA approves Truxima, first biosimilar for adults with non-Hodgkin lymphoma

November 28, 2018
The FDA today approved rituximab-abbs as a single agent or in combination with chemotherapy for the treatment of adults with CD20-positive, B-cell…
FDA News

FDA approves Hyrimoz, third Humira biosimilar

October 31, 2018
The FDA has approved the third biosimilar to adalimumab, adalimumab-adaz, for all eligible indications of the biologic product, according to a…
FDA News

FDA panel unanimously backs Rituxan biosimilar for lymphoma

October 10, 2018
The FDA’s Oncologic Drugs Advisory Committee voted 16-0 to support the licensure of CT-P10 as a rituximab biosimilar for three non-Hodgkin…
FDA News

FDA accepts BLA for Samsung Bioepis' Humira biosimilar

September 27, 2018
The FDA has accepted for review a Biologics License Application from Samsung Bioepis for its Humira biosimilar, according to a company press release…